Skip to content

Using Homeostatic Model Assessment of Insulin Resistance to Improve Metabolic Dysfunction-Associated Steatotic Liver Disease Risk Stratification in Individuals with Type 2 Diabetes from Primary Care and Endocrinology Settings.

Oct 2026 · Endocrine Practice · 0 citations · 42 references
Medicine

Abstract

Objectives

Current metabolic dysfunction-associated steatotic liver disease (MASLD) guidelines recommend fibrosis screening in individuals with type 2 diabetes (T2D) because of their increased risk of clinically significant fibrosis (≥F2). However, fibrosis risk is variable, and clinical tools to identify individuals at lower risk are lacking. We evaluated whether assessment of insulin resistance by homeostatic model assessment of insulin resistance (HOMA-IR) could improve risk stratification for clinically significant fibrosis.

Methods

We prospectively recruited 501 adults with T2D from primary care and endocrinology clinics. Participants were classified as insulin-resistant (HOMA-IR ≥2.5; n=350) or insulin-sensitive (HOMA-IR <2.5; n=151). Liver steatosis was assessed using VCTE, MRI/MRE, or liver biopsy according to the most accurate test, and the prevalence of clinically significant fibrosis (≥F2) was compared between groups.

Results

Insulin-resistant participants had higher prevalence of clinically significant fibrosis than insulin-sensitive participants (≥F2: 10% vs. <1%; p<0.001). They also had greater hepatic steatosis, higher ALT, AST, CK-18, HbA1c, and adipose tissue insulin resistance (Adipo-IR) levels, and lower adiponectin concentrations (all p<0.001). Fibrosis was infrequent among insulin-sensitive participants and almost exclusively limited to mild fibrosis (stage F1). Among participants with steatosis, ≥F2 fibrosis was present in 1% of insulin-sensitive participants compared with 13% of insulin-resistant participants (p<0.001).

Conclusions

Clinically significant fibrosis (≥F2) was uncommon among insulin-sensitive individuals with T2D and largely limited to mild fibrosis (F1). HOMA-IR <2.5 identified a subgroup at very low risk for fibrosis, supporting its potential use as a simple, clinically accessible tool for MASLD risk stratification in primary care and endocrinology settings.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.